65.75
+3.95%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Brooks Laboratories
Its shares trade on NSE under the ticker BROOKS.NS. It has been listed since 2 September 2011. In the fiscal year to 31 March 2026, it reported revenue of ₹857.4m and net income of ₹245.8m. At that date it held total assets of ₹1.48bn and shareholders' equity of ₹1.23bn.
Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, among others. The firm has manufacturing plants at Baddi, Himachal Pradesh. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 2 Sept 2011
- Employees
- 296
- Website
- brookslabs.net ↗
Leadership
Pay as last reported
- Mr. Prashant RathiChief Financial Officer
- Mr. Rajesh MahajanPresident - Procurement, since 2002₹9.6m
- Ms. Krutika RaneCompliance Officer, Company Secretary
- Dr. Durga MaityWhole-Time Director, since 2010₹1.9m
- Mr. Bhushan RanaWhole-Time Director, since 2023₹2.3m
- Mr. Jitendra SinghWhole-Time Director, since 2022₹870,000
- Mr. Lalit MahajanNon-Executive Independent Director₹30,000
- Mr. Manav MahajanNon-Executive Independent Director₹15,000
- Ms. Usha SinghNon-Executive Independent Director₹45,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Brooks Laboratories Ltd. manufactures Carbapenem products like Imipenem 250mg + Cilastatin 250mg in Mumbai, India.
- The company operates through the Pharmaceuticals segment with 296 employees in Mumbai.
- Brooks Laboratories has manufacturing plants in Baddi, Himachal Pradesh for pharmaceutical production.
Weaknesses
- Brooks Laboratories Ltd. has no manufacturing plants outside Baddi, Himachal Pradesh.
- The company's product range is limited to Carbapenem, Penicillins, and General categories.
- Brooks Laboratories Ltd. does not have international manufacturing facilities beyond Baddi.
Opportunities
- Brooks Laboratories can expand its Carbapenem product line to include Meropenem 1000mg+Sulbactam 500mg.
- The company can target regulated markets for its liquid injections like Iron sucrose 100mg/5ml.
- Brooks Laboratories can leverage its Mumbai headquarters to enter new international markets.
Threats
- Brooks Laboratories faces competition from other pharmaceutical companies in the Carbapenem category.
- The company's reliance on Baddi, Himachal Pradesh for manufacturing poses supply chain risks.
- Regulatory changes in international markets could affect Brooks Laboratories' product sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.